Mobocertinib, also known as Mobosertib, Exkivity, or TAK-788, is a targeted therapy drug for treating non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The drug is available in various versions, each with its own price point. This article will provide a detailed overview of the different versions of Mobocertinib and their respective prices.

Mobocertinib Different Versions and Prices

Understanding the different versions of Mobocertinib and their prices can help patients make informed decisions about their treatment options. Here is a breakdown of the available versions and their costs:

Original Research Drug

The original research version of Mobocertinib is produced by Takeda Pharmaceutical Company Limited, a Japanese company. This version is available in two main forms:

• Japanese Original Version: The specifications are 40mg * 120 tablets, and the price is approximately $37,287 per box.
• Takeda Hong Kong Clinical Version: The specifications are 40mg * 30 tablets, and the price is approximately $138 per box.

These prices reflect the high cost of research and development for new drugs. Patients should consider these costs when deciding on treatment options.

Generic Drugs

Several companies produce generic versions of Mobocertinib, which are more affordable alternatives to the original research drug. Here are the details:

• Lao Luoxius Version: Specifications are 40mg * 120 capsules, and the price is approximately $740 per box.
• Paraguay Boklong Version: Specifications are 40mg * 60 tablets, and the price is approximately $412 per box.

These generic versions offer a more accessible option for patients who may not be able to afford the original research drug. However, it is essential to purchase from reputable sources to ensure the quality and safety of the medication.

Other Generic Versions

There are additional generic versions of Mobocertinib available, including:

• Indian Luoxius Version: Specifications and pricing are similar to the Lao Luoxius version, but the exact price may vary slightly.
• Bolivia Lafaipe Version: Specifications are 40mg * 60 tablets, and the price is approximately $350 per box.

Patients should consult with their healthcare provider to determine the best version of Mobocertinib for their specific needs and budget. It is also important to verify the authenticity and quality of the medication before use.

Using Mobocertinib: Important Considerations

While Mobocertinib is an effective treatment for NSCLC with EGFR exon 20 insertion mutations, it is crucial to be aware of potential side effects and precautions. Here are some important considerations for using Mobocertinib:

QTc Prolongation and Torsades de Pointes

Mobocertinib can cause life-threatening prolongation of the corrected QT interval (QTc), including potentially fatal torsades de pointes. Before starting treatment, assess the QTc and baseline electrolyte levels. Correct any abnormalities in sodium, potassium, calcium, and magnesium. Regularly monitor QTc and electrolyte levels during treatment. Increase monitoring frequency for patients with risk factors for QTc prolongation, such as congenital long QT syndrome, heart disease, or electrolyte imbalances. Avoid concurrent use of drugs known to prolong the QTc interval and strong or moderate CYP3A inhibitors, which can further prolong the QTc. Adjust the dosage or discontinue Mobocertinib based on the severity of QTc prolongation.

Interstitial Lung Disease (ILD)/Pneumonia

Mobocertinib can cause fatal interstitial lung disease (ILD)/pneumonia. Monitor patients for new or worsening pulmonary symptoms that may indicate ILD/pneumonia. Immediately discontinue Mobocertinib if ILD/pneumonia is suspected, and permanently discontinue the drug if ILD/pneumonia is confirmed.

Cardiac Toxicity

Mobocertinib can lead to cardiac toxicity, including reduced ejection fraction, cardiomyopathy, and congestive heart failure, which can result in fatal heart failure. Monitor heart function, including baseline and periodic assessments of left ventricular ejection fraction. Adjust the dosage or discontinue Mobocertinib based on the severity of cardiac toxicity.

By being aware of these potential risks and taking appropriate precautions, patients can maximize the benefits of Mobocertinib while minimizing the risks. Always follow the guidance of your healthcare provider and report any unusual symptoms promptly.